MASTL

Across TCGA pan-cancer cohorts, MASTL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MASTL data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MASTL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MASTL expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LUAD are the cancer types where MASTL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.973	0.166	.010	49	view →
GBM	DFS	Median	All	0.870	0.547	.001	15	view →
LUAD	DFS	Median	III,IV	0.829	0.270	.009	11	view →
PDAC	OS	Median	All	0.915	0.174	.024	6	view →
LSCC	DFS	Quartile	All	0.988	0.922	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MASTL–HNSC (OS)

Open the HNSC breakdown →